clinical study insights by Richard Lafayette, MD, FACP; Carla M. Nester, MD, MSA, FASN; and Jai Radhakrishnan, MD, MS
There is hope that advancements in the science of complement inhibition will allow clinicians to do more for their patients with complement-driven ......READ MORE
expert roundtables by Richard Lafayette, MD, FACP; Carla M. Nester, MD, MSA, FASN; and Jai Radhakrishnan, MD, MS
There may be a rationale for studying complement-targeting strategies in etiologically distinct glomerular diseases such as complement 3 glomerulop......READ MORE
patient care perspectives by Jai Radhakrishnan, MD, MS
Complement 3 glomerulopathy (C3G) shares many clinicopathologic features with infection-related glomerulonephritis (IRGN), including acute nephriti......READ MORE
clinical topic updates by Jai Radhakrishnan, MD, MS
The term monoclonal gammopathy of renal significance (MGRS) describes a scenario in which a patient with monoclonal gammopathy of undetermined sign......READ MORE
expert roundtables by Richard Lafayette, MD, FACP; Carla M. Nester, MD, MSA, FASN; and Jai Radhakrishnan, MD, MS
Although immunoglobulin A nephropathy (IgAN) and complement 3 glomerulopathy (C3G) are distinct kidney diseases, certain aspects of their pathogene......READ MORE
clinical topic updates by Jai Radhakrishnan, MD, MS
Autoimmunity and genetic susceptibility are both implicated in immunoglobulin A nephropathy (IgAN) and complement 3 glomerulopathy (C3G). While the......READ MORE
